Documentos relacionados

1. A quantitative systems pharmacology model of plasma potassium regulation by the kidney and aldosterone.
2. Long-term effect of eplerenone treatment in children with chronic allograft nephropathy.
3. [Three ages of spironolactone. Evolution of views on spironolactone capabilities in the treatment of patients with heart failure.]
4. [New clinical opportunities for mineralocorticoid receptor antagonists: focus on antifibrotic effects].
5. Spontaneous Remission of Primary Aldosteronism with Mineralocorticoid Receptor Antagonist Therapy: A Review.
6. Effect of spironolactone on vascular stiffness in hemodialysis patients: a randomized crossover trial.
7. Gene expression analysis to identify mechanisms underlying improvement of myocardial fibrosis by finerenone in SHR.
8. Low-dose spironolactone abates cardio-renal disorder by reduction of BAX/inflammasome expression in experimentally induced polycystic ovarian syndrome rat model.
9. Concise and Free-Metal Access to Lactone-Annelated Pyrrolo[2,1-<i>a</i>]isoquinoline Derivatives via a 1,2-Rearrangement Step.
10. Spironolactone as a potential new pharmacotherapy for alcohol use disorder: convergent evidence from rodent and human studies.